People’s Daily Online, Beijing, March 16 (Reporter Zhang Wenting) Increase antigen testing, implement centralized isolation management of mild cases, and strengthen the application of non-drug therapy of traditional Chinese medicine… Recently, the National Health and Health Commission issued the “New Coronavirus Pneumonia”. “Diagnosis and Treatment Plan (Trial Version 9)”, according to the transmission characteristics and case characteristics of mutant strains such as Delta and Omicron, a series of revisions have been made on the medical treatment of new coronary pneumonia.
At present, the novel coronavirus pneumonia continues to spread worldwide. The Omicron strain has replaced the Delta strain as the main epidemic strain. The clinical manifestations of patients with novel coronavirus pneumonia are new Moreover, new drugs for the treatment of new coronavirus pneumonia have been launched one after another, and the treatment experience and treatment methods have been further enriched. In order to further scientifically and standardize the diagnosis and treatment of novel coronavirus pneumonia, the “Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)” has been revised from five aspects:
The first is to optimize case discovery and reporting procedures. On the basis of nucleic acid detection, antigen detection is added as a supplement to further improve the ability of early detection of cases. At the same time, the efficiency of diagnosing or excluding suspected cases is improved, and those with positive antigen test results are required to undergo nucleic acid testing immediately or closed-loop transfer to a qualified higher-level medical institution for nucleic acid testing. Those with a positive nucleic acid test result will be quarantined in a centralized manner or sent to a designated hospital for treatment, and will be reported directly online in accordance with regulations.
The second is to classify and treat cases. According to the opinions reflected in various places, such as “patients with Omicron variant strains are mainly asymptomatic infections and mild cases, most of them do not require excessive treatment, and all admission to designated hospitals will take up a lot of medical resources” and other opinions, the classification of cases has been further improved. Treatment measures:
1. Mild cases are subject to centralized isolation management, and relevant centralized isolation places cannot isolate inbound personnel, close contacts and other groups at the same time. During the isolation management period, symptomatic treatment and condition monitoring should be done. If the condition worsens, it should be transferred to a designated hospital for treatment.
2. Ordinary, severe, critical cases and cases with severe high-risk factors should be centrally treated in designated hospitals. Severe and critical cases should be admitted to ICU for treatment as soon as possible, and patients with high-risk factors and prone to severe disease should also be treated Admission to ICU treatment.
The third is to further standardize antiviral treatment. Two specific anti-new coronavirus drugs approved by the State Food and Drug Administration were written into the diagnosis and treatment plan, namely: PF-07321332/ritonavir tablet (Paxlovid) and domestic monoclonal antibody (ambavirumab/romisevir) monoclonal antibody injection).
Fourth, the content of TCM treatment has been revised and improved. Combined with the clinical treatment experience in various places, the application of non-drug therapy of traditional Chinese medicine was strengthened, and the content of acupuncture and moxibustion treatment was added; combined with the characteristics of children, the content of traditional Chinese medicine for children was added.
The fifth is to adjust the management of release from isolation and discharge standards, as well as the precautions for management of release from isolation and after discharge. Relevant domestic studies have shown that when the nucleic acid Ct value of infected persons in the recovery period is greater than or equal to 35, the virus cannot be isolated from the samples, and close contacts have not been found to be infected. Accordingly, the new version of the diagnosis and treatment plan will change the “two consecutive negative nucleic acid tests of respiratory specimens (sampling time interval of at least 24 hours)” in the criteria for release from isolation and discharge to “two consecutive nucleic acid tests for the novel coronavirus N gene and ORF gene Ct” All values ≥ 35 (fluorescence quantitative PCR method, the cutoff value is 40, and the sampling time is at least 24 hours apart), or two consecutive new coronavirus nucleic acid tests are negative (fluorescence quantitative PCR method, the cutoff value is less than 35, and the sampling time is at least 24 hours apart) Hour)”. “Continue 14-day isolation management and health monitoring after discharge” is revised to “Release isolation management or continue to conduct 7-day home health monitoring after discharge”.